Breaking News

Crown Bioscience, Shin Nippon Biomedical Enter Strategic Pact

April 24, 2014

Will promote Crown’s translational services to clients in Japan

Crown Bioscience, Inc. has entered into a strategic partnership with Shin Nippon Biomedical Laboratories (SNBL), a Japan-based company that provides preclinical and clinical drug development services.
 
SNBL will promote Crown’s translational services to its clients in Japan, and will serve as the exclusive representative for Crown’s services, including its collection of Patient Derived Xenograft (PDX) models.The companies will also look to co-develop new models and services leveraging their respective expertise in oncology, diabetes and non-human primate model development.
 
The partnership expands Crown’s international presence following its recent expansion into Europe with the acquisition of PRECOS Ltd. in July 2013. SNBL also has facilities across Japan, the U.S., China, and Cambodia.  
 
Jean-Pierre Wery, president of Crown said, “This strategic partnership offers Crown an excellent opportunity to develop a greater understanding of the Japanese market in order to further develop unique cutting-edge models. It is the first time that SNBL has agreed to represent an overseas company in such a deal. We are delighted to be partnering with the largest preclinical contract research organization in Japan as part of our international business strategy to develop our services in the Far East.”
 
Ryoichi Nagata, chief executive officer and president of SNBL comments, “SNBL is committed to providing our customers with fast and precise results across the entire drug development spectrum, from early discovery research to late-stage clinical trials. This unique partnership with Crown will enable us to strengthen our service offering, and also to collaborate on a variety of pre-clinical projects, utilizing unique clinically relevant models, with a shared goal of improving patient care and treatment outcomes. Our expertise in preclinical development provides a perfect complement to Crown’s existing global services.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important